

SECOND DOSE COHORT INITIATED IN CLTX CAR T PHASE 1 TRIAL

HIGHLIGHTS

- The 1st patient in the 2nd dose cohort of the CLTX CAR T cell clinical trial at the City of Hope, a world-renowned cancer treatment and research center near Los Angeles, has received dosing
 - Dosing of the 2nd dose cohort introduced dual intratumoral and intraventricular routes of dosing
-

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company, is pleased to announce the treatment of the first patient in the second dose cohort in City of Hope’s phase 1 clinical trial evaluating the safety and tolerability of Chimeric’s chlorotoxin CAR T (CLTX CAR T) cell therapy.

The treatment of the first patient in the second dose cohort marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing. This second dose cohort will receive a total target dose of 88×10^6 CLTX CAR T cells. City of Hope’s phase 1 clinical trial is expected to enroll 18-36 patients with MMP2+ progressive or recurrent glioblastoma over a 24-month period.

“We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration,” said Jennifer Chow, Chimeric Therapeutics Chief Operating Officer. “This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma.”

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHLOROTOXIN CAR T CELLS

Chlorotoxin CAR T (CLTX CAR T) cell therapy is a potentially best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent / progressive glioblastoma (GBM). Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.

CLTX CAR T cell therapy uniquely utilises chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumor targeting component of the chimeric antigen receptor (CAR). CLTX has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targets like EGFR, HER2 or IL13R α 2.

In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against GBM while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.

Chimeric believes that cellular therapies have the potential to cure cancer and that by combining their expertise in the development and commercialization of cell therapies with the world's most innovative scientists and science, they will be able to bring the promise of cell therapy to life for more patients.

Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the CLTX CAR T cell therapy which is currently in development for patients with progressive and recurrent glioblastoma and is also being investigated for development in patients with other solid tumors such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.

Chimeric Therapeutics is also currently actively engaged in enhancing their pipeline with innovative cell therapies for patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Operating Officer
P: 908-723-8387
E: jchow@chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au